Tag Archive for: crispr
CRISPR: Gene Breakthrough Could Starve Cancer Cells of Vitamin D
/in CRISPR, Preclinical Research/by MaxScientists Uncover Key Protein Driving Cancer Spread to Bone, ASH1L
/in CRISPR, Preclinical Research/by MaxASH1
ACBP: Scientists Identify Key Protein Driving Bone Metastasis, Pointing to New Therapeutic Strategies
/in CRISPR, Preclinical Research/by MaxCRISPR is Here to Stay: Gene Therapy Succesfully Used On An Infant With Incurable Disease
/in Not PCa related/by MaxTargeting the Undruggable: SCORT–Cas13d Nanotherapy Against Metastatic Prostate Cancer
/in CRISPR, Preclinical Research/by MaxOrally Delivered CRISPR Therapy, Groundbreaking Evolution
/in CRISPR, Not PCa related, Preclinical Research/by MaxAdvancements in Delivery: Gene Therapy Could Help Prostate Cancer Treatment
/in CRISPR, Delivery, Preclinical Research/by MaxCRISPR Strikes Again: Fat Cells Starve Tumors,A Revolutionary Approach to Cancer Treatment
/in CRISPR, Preclinical Research/by MaxTargeting LIG1 with PARP Inhibitors: E New Target Identified Using CRISPR
/in CRISPR, PARPi, Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Phase 3 DASL-HiCaP: Darolutamide Reduces Metastasis Risk in High-Risk Prostate Cancer October 24, 2026
- UPDATE: PROTEUS Substudy Shows Improved Event-Free Survival With Perioperative Apalutamide October 24, 2026
- UPDATE: Bavdegalutamide Shows Stronger Activity in Prostate Cancers With Specific AR Mutations October 23, 2026
- UPDATE: TheraPb Reports 11.2-Month Median rPFS With 212Pb-ADVC001 October 23, 2026